Chemistry:Noribogainalog

From HandWiki

Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine.[1][2] It is a simplified analogue of noribogaine.[1][2]

Pharmacology

The drug acts as a potent serotonin 5-HT2A receptor partial agonist (EC50 ≈ 90 nM; Emax = 35%).[2] It also has activity as a dopamine transporter (DAT) chaperone.[3] Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures.[2] However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin.[2] The drug shows relatively low expected blood–brain barrier permeability.[2]

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature 589 (7842): 474–479. January 2021. doi:10.1038/s41586-020-3008-z. PMID 33299186. Bibcode: 2021Natur.589..474C. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors". Biomedicine & Pharmacotherapy 184. March 2025. doi:10.1016/j.biopha.2025.117887. PMID 39938347. 
  3. ↑ "Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones". Frontiers in Cellular Neuroscience 16. 2022. doi:10.3389/fncel.2022.832536. PMID 35614973. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Noribogainalog&oldid=4037838"